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ABSTRACT 
Objective: The present work aimed to synthesize New series of pyrazoles 3 and pyrazolo[1,5-a]pyrimidines 5, 7, 9 in order to evaluate their 
antiproliferative activity against human breast adenocarcinoma MCF-7cell line and study the cell cycle progression of the most active compounds. In 
addition, Pharmacophore modeling and QSAR Studies of these new compounds were done. 
Methods: The diazonium salt of 4-aminoacetophenone 1 was coupled with malononitrile in ethanol using sodium acetate affords 2-[(4-
acetylphenyl)diazenyl] malononitrile Cycloaddition of hydrazine hydrate, in molar ratios 1:1 or 1:2, on compound 2, furnished 3,5-
diaminopyrazolederivatives 3a and 3b respectively. Moreover, new pyrazolo[1,5-a]pyrimidine derivatives 5a-f were obtained upon 
cyclocondensation of 3a, b with different chalcones 4a-c in EtOH/piperidine,while compounds 7a-f were prepared via cycloaddition of 3a, b with 
various arylidene malononitriles 6a-c in the same reaction condition. Finally, treatment of 3a, b with ethyl 2-cyano-3-ethoxyacrylate 8a or 2-
(ethoxymethylene)malononitrile 8b in EtOH/TEA yielded the novel pyrazolo[1,5-a]pyrimidine derivatives 9a, b respectively. These target 
compounds were screened for their cytotoxic activity against MCF-7 (human breast Cell Line) followed by study cell cycle of 7a. Finally, 
Pharmacophore modeling and QSAR Studies was carried out.  
Results: The pyrazolopyrimidine 7a was the most active compound (IC50 = 3.25 µM), whereas, some of the tested compounds exploited moderate 
growth inhibitory activity. Its effect was further studied on cell cycle progression; results showed that compound 7a induced cell cycle arrest at S-
phase verifying this compound as a promising selective anticancer agent. 
Conclusion: Compound 7a was found to be the most active member against MCF-7 breast cancer (IC50= 3.25 μM), Further biological assessment of 
7a using flow-cytometric analysis, revealed that it induced cell cycle arrest at S phase.  
Keywords: Pyrazole, Pyrazolo[1,5-a]pyrimidine, MCF-7 breast cancer cell line, Cell cycle profile, 3D pharmacophore,1 QSAR study 
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INTRODUCTION 
Cancer is one of the most devastating diseases responsible for 
human loss worldwide. Although there have been great advances in 
the detection and treatment of cancer, it remains one of the greatest 
medical challenges [1]. Breast cancer is one of the most common 
cancers in women. Despite the advances in the treatment of most 
types of solid tumors (e. g. breast and ovarian cancers) the survival 
rates are still significantly low [2]. 
Additionally, chemotherapy in breast cancer treatment has many 
undesirable side effects. These facts clearly emphasize the need to 
develop novel effective chemotherapeutic agents [3, 4]. One of the 
new approaches to cancer therapy is targeting the cell cycle 
regulation. The cell cycle is controlled and regulated by various 
mechanisms in mammalian cells. The cell cycle is divided into four 
phases, G1, S, G2, and M phase. Between these phases are the 
checkpoints, which control the commitment of the cell to further 
progress. The two extensively studied checkpoints appear at the 
G1/S and G2/M boundaries. When checkpoint arrest controls are 
compromised, this leads to cell cycle dysregulation leading to 
cancerous cells. Hence, molecules that act as decision makers at 
these checkpoints are good targets for the cancer treatment [5]. 
Pyrazole and pyrazolo [1,5-a]pyrimidine have emerged as potential 
pharmacophore scaffolds and have been extensively used to design 
various antitumor agents (fig. 1). For example, the two aryl 
pyrazoles in the market, Ruxolitinib (Jakavi®, Novartis) I [6] and 
Crizotinib (XALKORI®) II [7], (Fig.1), in addition to the N'-(1-{1-[4-
nitrophenyl]-3-phenyl-1H-pyrazol-4-yl} methylene)-2-chlorobenzo-
hydrazide III which displayed significant activity against MCF-7 cell 
line [8]. 
 
Fig. 1: Pyrazole and pyrazolo [1,5-a] pyrimidine scaffolds based 
potential candidates and drugs 
 
Moreover, several pyrazolopyrimidines were effective against 
different cellular and enzymatic targets involved in dysregulated 
signaling, for example, the B-Raf kinase inhibitor IV [9] and the 
cyclin-dependent kinase inhibitor V [10]. It has also been 
demonstrated that the pyrazolo [1,5-a]pyrimidine scaffold itself 
interacts with the hinge region of many kinase enzymes [11].  
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 7, 2016 
Farrag et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 7, 434-442 
 
435 
Based on these findings and with the attempt to obtain potent 
anticancer agents the synthesis of new series of pyrazoles and 
pyrazolo [1,5-a] pyrimidines was adopted and evaluated as 
anticancer agents. 
In the present work, position 5 of the pyrazolo[1,5-a]pyrimidine 
scaffold, was replaced by a phenyl moiety, compounds 5a-f, or an 
amino group, compounds 7a-f, 9a, b, instead of the piperidinyl group 
in the previously prepared pyrazolopyrimidines VI-VIII. Position 3 
was occupied by arylazo moiety whereas position 2 had an amino 
group in all the series. Finally, generation of a 3D-pharmacophore 
model and a 2D QSAR model were combined to explore the 
structural requirements controlling the cytotoxic activities.  
MATERIALS AND METHODS 
General 
All chemicals were purchased from VWR International Merck, 
Germany or Sigma-Aldrich and used without further purification. 
Melting Points were carried out by open capillary tube method using 
Stuart SMP3 Melting Point apparatus and they are uncorrected. 
Elemental Microanalysis was carried out at the Regional Center for 
Mycology and Biotechnology, Al-Azhar University. Infrared spectra 
were recorded using potassium bromide discs on Bruker ATR/FTIR 
Spectrophotometer at the Armed Forces Laboratories. 1H NMR 
spectra were recorded on a Varian Gemini 300 MHz 
Spectrophotometer; the spectra were run at 300 MHz in deuterated 
dimethyl sulfoxide (DMSO-d6) at the Armed Forces Laboratories. 13C 
NMR Spectra were recorded on a Varian Gemini 300 MHz 
Spectrophotometer; the spectra were run at 300 and 400 MHz in 
deuterated dimethyl sulfoxide (DMSO-d6) at the Armed Forces 
Laboratories. Chemical shifts were expressed in δ units and were 
related to that of the solvents. As for the proton magnetic resonance, 
D2O was carried out for NH and OH exchangeable protons. Mass 
Spectra were recorded using Shimadzu Gas Chromatograph Mass 
spectrometer-Qp 2010 plus (Japan). All the reactions were followed 
by TLC using silica gel F254 plates (Merck), and were visualized by 




malononitriles 6a-c [14],2-(methoxy methylene) malononitrile 8a 
and ethyl 2-cyano-3-ethoxyacrylate 8b [15]were prepared according 
to the previously reported procedures. 
Synthesis of 1-(4-[(3,5-Diamino-1H-pyrazol-4-yl) diazenyl] 
phenylethanone 3a 
A mixture of 2 (0.01 mol) and hydrazine hydrate 98% (0.01 mol) 
was heated in 30 ml ethanol (95%) under reflux for 2 h. The solid 
product so formed was filtered off and crystallized from ethanol. 
Yield: 42%; mp 257-260 °C; IR (KBr): 3381, 3268 (NH2, NH), 1673 
(C=O), 1616 (C=N), 1551 (N=N) cm-1; 1HNMR (300 MHz, DMSO-d6): δ 
2.56 (s, 3H, CH3), 6.35 (br. s, 2H, NH2, D2O-exchangeable), 7.72-7.75 
(d, 2HAr-H2, 6,J = 8.4 Hz), 7.94-7.96 (d, 2H, Ar-H3, 5, J = 8.4 Hz), 10.80 
(s, 1H, NH, D2O-exchangeable.);13C NMR (400 MHz, DMSO-d6) δ 
(ppm): 27.09, 114.79, 120.63, 125.54, 129.73, 134.46, 152.91, 
157.40, 197.38; MS [m/z, %]: 244 [M+
Synthesis of 4-[(4-(1-Hydrazonoethyl)phenyl)diazenyl]-1H-
pyrazole -3,5-diamine 3b 
, 100]; Anal. calcd. for 
C11H12N6O (%): C, 54.09; H, 4.95; N, 34.41. Found: C, 54.22; H, 4.99; 
N, 34.70. 
A mixture of 2 (0.01 mol) and hydrazine hydrate 98% (0.02 mol) 
was heated in 30 ml ethanol (95%) under reflux for 2 h. The solid 
product so formed was filtered off and crystallized from ethanol. 
Yield: 43%; mp252-255 °C; IR (KBr): 3398, 3296 (NH2, NH), 1614 
(C=N),1589 (N=N)cmP-1P; P 1PHNMR (300 MHz, DMSO-d6) δ: 2.56 (s, 3H, 
CH3), 6.38 (s, 6H, 3NH2, D2O-exchangeable), 7.73-7.75 (d, 2H, Ar-H2, 6, 
J = 8.4 Hz), 7.94-7.97 (d, 2H, Ar-H3, 5, J = 8.4 Hz), 10.79 (s, 1H, NH, 
D2O-exchangeable); P13PC NMR (300 MHz, DMSO-d6) δ (ppm): 26.63, 
99.49, 116.64, 120.20, 125.06, 128.60, 129.28, 134.04, 156.82, 
156.87, 167.60; MS [m/z, %]: 258 [MP+P, 71.27]; Anal. calcd. for 
C11H14N8 (%): C, 51.31; H, 5.49; N, 43.62. Found: C, 51.15; H, 5.46; N, 
43.38. 
General procedure for the synthesis of pyrazolo [1, 5-a] 
pyrimidines 5a-f 
A mixture of equimolar amounts of 3a or 3b and the appropriate 
substituted chalcones4a-c were refluxed for 5 h in ethanol (20 ml) 
containing 3 drops of piperidine. The separated crystalline product 
was filtered, dried and recrystallized from ethanol. 
1-(4-[(2-Amino-7-(4-chlorophenyl)-5-phenylpyrazolo [1,5-
a]pyrimidin-3-yl)diazenyl] phenylethanone 5a  
Yield: 38%; mp157-160 °C; IR (KBr): 3406, 3296 (NH2), 1672 (C=O), 
1614 (C=N,N=N) cmP-1P; P1PHNMR (300 MHz, DMSO-d6) δ: 2.62 (s, 3H, 
CH3), 6.51 (s, 2H, NH2, D2O-exchangeable), 7.78 (s, 1H, pyrimidine-
H), 7.81-8.40 (m, 13H, Ar-H, Ar`-H, Ph-H); P13PC NMR (300 MHz, DMSO-
d6) δ (ppm): 25.73, 88.05, 104.21, 121.00, 125.27, 127.32, 128.32, 
128.84, 129.42, 131.68, 135.72, 136.38, 144.31, 147.56, 152.18, 
155.89, 197.10; MS [m/z, %]: 468 [M P+P+2, 14.57], 466 [M+ , 40.46]; 
Anal. calcd. for C26H19ClN6O (%): C, 66.88; H, 4.10; N,18.00. Found: C, 
67.03; H, 4.14; N, 18.18. 
1-(4-[(2-Amino-5-phenyl-7-(p-tolyl)pyrazolo[1,5-a]pyrimidin-
3-yl)diazenyl] phenylethanone 5b  
Yield: 50%; mp 153-155 °C; IR (KBr): 3406 (br. NH2), 1676, (C=O), 
1608 (C=N,N=N) cm-1; 1HNMR (300 MHz, DMSO-d6): 2.46 (s, 3H, 
CH3), 2.62 (s, 3H, CH3-CO), 6.50 (s, 2H, NH2, D2O-exchangeable), 7.43-
7.46 (d, 2H, Ar`-H3, 5), 7.78 (s, 1H, pyrimidine-H), 7.97-8.39 (m, 11H, 
Ar-H, Ph-H); 13C NMR (400 MHz, DMSO-d6) δ (ppm): 21.57, 27.22, 
115.52, 121.47, 121.51, 125.77, 127.86, 128.15, 128.66, 128.88, 
129.36, 129.94, 130.21, 130.25, 130.28, 136.99, 140.19, 141.54, 
146.04, 152.31, 152.65, 156.70, 197.00; MS [m/z, %]: 446 [M+, 
34.74]; Anal. calcd. for C27H22N6O (%): C, 76.63; H, 4.97; N,18.82. 
Found: C, 72.89; H, 5.08; N, 19.04. 
1-(4-[(2-Amino-5-phenyl-7-(3,4,5-
trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-
yl)diazenyl]phenylethanone 5c  
Yield: 33%; mp 222-225 °C; IR (KBr): 3412, 3280 (NH2), 1676 (C=O), 
1622 (C=N,N=N) cm-1; 1HNMR (300 MHz, DMSO-d6) δ: 2.63 (s, 
3H,CH3), 3.79 (s, 3H, OCH3), 3.91 (s, 6H, 2OCH3), 7.09 (s, 2H, NH2, 
D2O-exchangeable), 7.44 (s, 2H, NH2, D2O-exchangeable), 7.54 (s, 2H, 
H2, 6, Ar`-H) 7.59-7.80 (m, 5H, Ph-H), 7.96, (s, 1H, pyrimidine-H), 
7.98-7.96 (d, 2H, Ar-H,2, 6J = 8.4 Hz), 8.10-8.12 (d, 2H, Ar-H3, 5, J = 8.4 
Hz);13C NMR (300 MHz, DMSO-d6) δ (ppm): 26.67, 48.98, 56.26, 
60.12, 106.37, 107.82, 107.93, 116.17, 121.02, 125.42, 127.41, 
128.88, 129.43, 130.76, 135.65, 136.32, 139.79, 145.57, 147.98, 
152.10, 152.55, 155.95, 156.61, 197.07; MS [m/z, %]: 522 [M+, 
26.31]; Anal. calcd. for C29H26N6O4(%): C, 66.66; H, 5.02; N,16.08. 
Found: C, 66.89; H, 5.11; N, 16.31. 
7-(4-Chlorophenyl)-3-[(4-(1-hydrazonoethyl)phenyl)diazenyl]-
5-phenylpyrazolo[1,5-a]pyrimidin-2-amine 5d  
Yield: 28%; mp 220-222 °C; IR (KBr): 3417, 3377(2NH2), 1614 
(C=N,N=N) cm-1; 1HNMR (300 MHz, DMSO-d6) δ: 2.05 (s, 3H, CH3), 
6.40 (s, 2H, NH2, D2O-exchangeable), 6.49 (s, 2H, NH2, D2O-
exchangeable), 7.27-7.46 (m, 3H, Ph-H), 7.58-7.80 (m, 7H, 2 Ph-H, 
4Ar-H) & pyrimidine-H), 8.22-8.25 (d, 2H, Ar-H2, 6), 8.38-8.42 (d, 2H, 
Ar-H3, 5);13C NMR (400 MHz, DMSO-d6) δ (ppm): 11.74, 58.82, 
115.52, 121.50, 125.77, 126.61, 127.82, 128.95, 129.30, 129.38, 
129.87, 131.21, 132.19, 132.70, 136.23, 136.88, 141.73, 142.08, 
144.82, 147.90, 152.27, 156.77; MS [m/z]: MS [m/z, %]: 482 [M+2 +, 
31.11], 480 [M+ , 24.78]; Anal. calcd. for C26H21ClN8 (%): C, 64.93; H, 
4.40; N, 23.30. Found: C, 65.08; H, 4.46; N, 23.45. 
3-[(4-(1-Hydrazonoethyl)phenyl)diazenyl]-5-phenyl-7-(p-
tolyl)pyrazolo[1,5-a]pyrimidin-2-amine 5e  
Yield: 40%; mp 185-190 °C; IR (KBr): 3379, 3278 (NH2), 1616 
(C=N,N=N) cm-1; 1HNMR (300 MHz, DMSO-d6) δ: 2.28 (s, 3H, CH3), 
2.38 (s, 3H, N=C-CH3), 6.49 (s, 2H, NH2, D2O-exchangeable), 7.19-7.22 
(d, 2H, Ar`-H3, 5), 7.28 (s, 2H, NH2, D2O-exchangeable), 7.40-7.46 (m, 
3H, Ph-H), 7.58-7.80 (m, 5H, 2 Ar-H2,6+2 Ar`-H2,6+pyrimidine-H), 
8.11-8.14 (d, 2H, Ph-H), 8.39-8.42 (m, 2H, Ar-H3, 5);13C NMR (300 
MHz, DMSO-d6) δ (ppm): 11.22, 26.54, 58.82, 101.34, 120.19, 124.86, 
Farrag et al. 
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125.09, 128.34, 128.75, 129.03, 129.39, 129.89, 131.21, 132.19, 
132.70, 136.23, 137.92, 141.84, 144.72, 147.00, 152.41, 168.00; MS 
[m/z, %]: 461 [M++1, 4.29]; Anal. calcd. for C27H24N8 (%): C, 70.42; H, 
5.25; N, 24.33. Found: C, 70.60; H, 5.29; N, 24.47. 
3-[(4-(1-Hydrazonoethyl)phenyl)diazenyl]-5-phenyl-7-(3,4,5-
trimethoxyphenyl) pyrazolo[1,5-a]pyrimidin-2-amine 5f  
Yield: 35%; mp 138-140 °C; IR (KBr): 3293 (br. 2NH2), 1600 
(C=N,N=N) cm-1; 1HNMR (300 MHz, DMSO-d6) δ: 2.34 (s, 3H, CH3), 
3.79 (s, 3H, OCH3), 3.91 (s, 6H, 2OCH3), 6.53 (s, 2H, NH2, D2O-
exchangeable), 7.44 (s, 2H, NH2, D2O-exchangeable), 7.54 (s, 2H, Ar`-
H2, 6), 7.49-7.62 (m, 9H, Ar-H, Ph-H), 8.41 (s, 1H, pyrimidine-H); 13C 
NMR (300 MHz, DMSO-d6) δ (ppm): 26.78, 56.25, 56.31, 71.20, 
106.49, 107.80, 107.97, 116.17, 121.04, 125.44, 127.41, 128.94, 
129.45, 135.66, 136.33, 145.58, 147.98, 152.11, 152.57, 155.95, 
156.63, 197.09; MS [m/z, %]: 536 [M+, 8.89]; Anal. calcd. for 
C29H28N8O3 (%): C, 64.91; H, 5.26; N, 20.88. Found: C, 65.12; H, 5.30; 
N, 21.09. 
General procedure for the synthesis of pyrazolo [1, 5-a] 
pyrimidines 7a-f 
Equivalent amounts of 3a or 3b and appropriate arylidene-
malononitriles 6a-c were heated under reflux in ethanol (20 ml) and 
piperidine (3-4 drops) for 4 h, pyrazolo[1,5-a]pyrimidines were 
precipitated on hot, filtered, dried and crystallized from absolute ethanol. 
3-[(4-Acetylphenyl)diazenyl]-2,5-diamino-7-(4-chlorophenyl) 
pyrazolo[1,5a]pyrimidine-6-carbonitrile 7a  
Yield: 48%, mp 227-230 °C; IR (KBr): 3402, 3302 (2NH2), 2212 (CN), 
1660 (C=O), 1616 (C=N,N=N) cm-1; 1HNMR (300 MHz, DMSO-d6): 
2.60 (s, 3H, CH3), 7.23 (s, 2H, NH2, D2O-exchangeable), 7.67-7.74 (m, 
4H, Ar`-H), 7.90-8.15 (m, 4H, 4-Cl-Ar-H), 8.67 (s, 2H, NH2, D2O-
exchangeable); 13C NMR (300 MHz, DMSO-d6) δ (ppm): 26.64, 
117.64, 120.13, 127.42, 128.53, 129.75, 130.43, 134.02, 134.96, 
136.05, 148.79, 151.91, 154.97, 155.57, 156.86, 186.77, 197.36; MS 
[m/z, %]: 432 [M++2, 1.07], 430 [M+, 1.31]; Anal. calcd. for 
C21H15ClN8O (%): C, 58.54; H, 3.51; N, 26.01. Found: C; 58.71 H, 3.49; 
N, 26.28. 
3-[(4-Acetylphenyl)diazenyl]-2,5-diamino-7-(4-methoxyphenyl) 
pyrazolo[1,5-a]pyrimidine-6-carbonitrile 7b  
Yield: 57%; mp 162-165 °C; IR (KBr): 3398, 3300 (2NH2), 2210 (CN), 
1674 (C=O), 1614 (C=N, N=N) cm-1; 1HNMR (300 MHz, DMSO-d6) δ: 
2.57 (s, 3H, CH3), 3.87 (s, 3H, OCH3), 7.12-7.14 (d, 2H, Ar`-H3, 5,), 7.18 
(s, 2H, NH2, D2O-exchangeable), 7.21 (s, 2H, NH2, D2O-exchangeable), 
7.86-7.89 (m, 2H, H2, 6, Ar`-H), 7.95-7.97 (d, 2H, Ar-H2, 6, J = 8.4 Hz), 
8.08-8.06 (d, 2H, Ar-H 3, 5,J = 8.4 Hz); 13C NMR (400 MHz, DMSO-d6) δ 
(ppm): 27.08, 55.86, 76.18, 114.20, 116.78, 118.06, 120.72, 121.61, 
127.60, 129.91, 130.88, 136.40, 147.13, 149.44, 152.40, 156.14, 
157.36, 161.55, 197.36; MS [m/z, %]: 426 [M+, 72.60]; Anal. calcd. for 




Yield: 48%; mp 225-227 °C; IR (KBr): 3450, 3340 (2NH2), 2233 (CN), 
1674 (C=O), 1614 (C=N), 1589 (N=N) cm-1; 1HNMR (300 MHz, 
DMSO-d6): 2.59 (s, 3H, CH3), 3.74 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 
7.0-7.23 (m, 3H, Ar`-H), 7.86-7.89 (d, 2H, Ar-H2, 6, J = 8.4 Hz), 8.02-
8.05 (d, 2H, Ar-H3, 5, J = 8.4 Hz), 8.60 (s, 2H, NH2, D2O-exchangeable); 
13C NMR (300 MHz, DMSO-d6) δ (ppm): 26.66, 55.85, 78.69, 115.18, 
121.22, 129.39, 132.16, 136.05, 148.01, 147.00, 151.91, 152.29, 
155.57, 197.11; MS [m/z, %]: 456 [M+, 6.01]; Anal. calcd. for 
C23H20N8O3 (%): C, 60.52; H, 4.42; N, 24.55. Found: C, 60.74; H, 4.49; 
N, 24.69. 
2,5-Diamino-7-(4-chlorophenyl)-3-[(4-(1-hydrazonoethyl) 
phenyl)diazenyl]pyrazolo[1,5-a] pyrimidine-6-carbonitrile 7d  
Yield: 34%; mp 215-220 °C; IR (KBr): 3396, 3296, 3184 (3NH2), 
2208 (CN), 1614(C=N),1595 (N=N) cm-1; 1HNMR (300 MHz, DMSO-
d6) δ: 2.41 (s, 3H, CH3), 6.34 (s, 2H, NH2, D2O-exchangeable), 7.55-
7.58 (d, 2H, Ar`-H2, 6, J = 8.4 Hz), 7.63-7.66 (d, 2H, Ar`-H3, 5, J = 8.4 Hz), 
7.71-7.74 (d, 2H, Ar-H2, 6, J = 8.4 Hz), 7.89-7.92 (d, 2H, Ar-H3, 5, J = 8.4 
Hz), 10.76 (s, 2H, NH2, D2O-exchangeable); 13C NMR (300 MHz, 
DMSO-d6) δ (ppm): 14.75, 115.19, 120.15, 126.88, 127.45, 128.87, 
129.72, 133.33, 134.97, 147.00, 148.61, 152.03, 153.47, 154.97, 
156.41, 163.80, 169.00; MS [m/z, %]: 446 [M++2, 0.47], 444 [M+, 
1.13]; Anal. calcd. for C21H17ClN10 (%): C, 56.70; H, 3.85; N, 31.48. 
Found: C, 56.87; H, 3.92; N, 31.67. 
2,5-Diamino-3-[(4-(1-hydrazonoethyl)phenyl)diazenyl]-7-(4-
methoxyphenyl)pyrazolo[1,5-a]pyrimidine-6-carbonitrile 7e 
Yield: 41%; mp 190-192 °C; IR (KBr): 3427, 3303, 3223 (3NH2), 
2199 (CN), 1605 (C=N,N=N) cm-1; 1HNMR (300 MHz, DMSO-d6) δ: 
2.50 (s, 3H, CH3), 3.83 (s, 2H, NH2, D2O-exchangeable), 3.87 (s, 3H, 
OCH3), 7.08-8.63 (m, 8H, Ar-H);13C NMR (300 MHz, DMSO-d6) δ 
(ppm): 22.49, 55.30, 87.80, 113.76, 114.38, 117.06, 121.12, 126.98, 
127.58, 128.58, 130.40, 148.91, 153.77, 157.91, 160.45, 161.55, 
162.90, 169.9; MS [m/z, %]: 439 [M+-1, 4.28]; Anal. calcd. for 
C22H20N10O (%): C, 59.99; H, 4.58; N, 31.80. Found: C, 60.17; H, 4.66; 
N, 32.07. 
2,5-Diamino-7-(2,3-dimethoxyphenyl)-3-[(4-(1-hydrazonoethyl) 
phenyl)diazenyl] pyrazolo[1,5-a] pyrimidine-6-carbonitrile 7f 
Yield: 48%; mp 288-290 °C; IR (KBr): 3392, 3298, 3168 (3NH2), 
2179 (CN) cm-1; 1HNMR (300 MHz, DMSO-d6) δ: 2.34 (s, 3H, CH3), 
3.83, 3.86 (2s, 6H, 2OCH3), 6.21 (s, 2H, NH2, D2O-exchangeable), 7.63 
(m, 3H, Ar`-H), 7.72-7.75 (d, 2H, Ar-H2, 6, J = 8.4 Hz), 7.97-7.94 (d, 2H, 
Ar-H3, 5, J = 8.4 Hz), 10.75 (s, 2H, NH2, D2O-exchangeable); 13C NMR 
(300 MHz, DMSO-d6) δ (ppm): 14.64, 66.3, 114.99, 120.16, 125.06, 
127.13, 127.45, 135.64, 154.53, 157.56; MS [m/z, %]: 470 [M+, 
4.16];Anal. calcd. for C23H22N10O2 (%): C, 58.71; H, 4.71; N, 29.77. 
Found: C, 58.97; H, 4.76; N, 29.8 
General procedure for the synthesis of pyrazolo[1,5-
a]pyrimidines 9a, b 
Equimolar amounts of 3a and ethyl 2-cyano-3-ethoxyacrylate 8a 
or 3b and ethoxymethylenemalononitrile 8b were heated under 
reflux for 6 h in ethanol (20 ml) and 5 drops of triethylamine. 




Yield: 45%, mp 291-293 °C; IR (KBr): 3425, 3309 (2NH2), 1720 (C=O 
ester),1670 (C=O),1616 (C=N),1589 (N=N) cm-1; 1HNMR (300 MHz, 
DMSO-d6) δ: 1.33-1.37 (t, 3H, CH2CH3), 2.61 (s, 3H, CH3), 4.34-4.37 
(q, 4H, CH2CH3), 7.18 (s, 2H, NH2, D2O-exchangeable), 7.88-8.09 (m, 
4H, Ar-H), 8.69 (s, 1H, pyrimidine-H);13C NMR (400 MHz, DMSO-d6) 
δ (ppm): 14.67, 27.25, 61.18, 110.00, 121.63, 127.02, 127.12, 129.93, 
136.47, 147.83, 152.24, 152.79, 156.14, 161.50, 197.00; MS [m/z, 
%]: 367 [M+, 1.75]; Anal. calcd for C17H17N7O3 (%): C, 55.58; H, 4.66; 
N, 26.69. Found: C, 55.81; H, 4.69; N, 26.78. 
2,5-Diamino-3-(4-(1-hydrazonoethyl) phenyl) diazenyl) 
pyrazolo[1,5-a]pyrimidine-6-carbonitrile 9b  
Yield: 55%, mp 293-295 °C; IR (KBr): 3396, 3302, 3265 (2NH2), 2214 
(CN), 1612 (C=N,N=N) cm-1; 1HNMR (300 MHz, DMSO-d6) δ: 2.34 (s, 
3H, CH3), 6.38 (s, 2H, NH2, D2O-exchangeable), 7.64 (s, 1H, pyrimidine-
H), 7.75-7.97 (m, 4H, Ar-H), 10.79 (s, 4H, 2NH2, D2O-exchangeable);13C 
NMR (300 MHz, DMSO-d6) δ (ppm): 14.64, 66.95, 115.00, 120.18, 
121.13, 127.09, 127.42, 135.63, 147.84, 151.80, 154.53, 157.56, 
168.26; MS [m/z]: 334[M+, 5.91] ; Anal. calcd. for C15H14N10 (%): C, 
53.89; H, 4.22; N, 41.89. Found: C, 54.08; H, 4.26; N, 42.13. 
Biological assay 
Cell culture 
Cancer cells from breast cancer cell line (MCF-7, human breast 
adenocarcinoma) was purchased from American type Cell Culture 
collection (ATCC, Manassas, USA) and grown on the appropriate 
growth medium Dulbecco's modified Eagle's medium (DMEM) or 
Roswell Park Memorial Institute medium (RPMI 1640) 
supplemented with 100 mg/ml of streptomycin, 100 units/ml of 
penicillin and 10% of heat-inactivated fetal bovine serum in a 
humidified, 5% (v/v) CO2 atmosphere at 37 °C. 
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Cell growth inhibitory assay 
Cytotoxicity was determined using 3-[4,5-dimethylthiazole-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) method. Exponentially 
growing cells were trypsinized, counted and seeded at the 
appropriate densities (2000-1000 cells/0.33 cm2 well) into 96-well 
microtiter plates. Cells then were incubated in a humidified 
atmosphere at 37̊ C for 24 h. Then, cells were exposed to different 
concentrations of compounds (0.1, 10, 100, 1000 µM) for 72 h. Then 
the viability of treated cells was determined using MTT technique as 
follow. Media were removed; cells were incubated with 200 μl of 5% 
MTT solution/well (Sigma-Aldrich, MO) and were allowed to 
metabolize the dye into colored-insoluble formazan crystals for 2 h. 
The remaining MTT solution was discarded from the wells, and the 
formazan crystals were dissolved in 200 µl/well-acidified 
isopropanol for 30 min, covered with aluminum foil and with 
continuous shaking using a MaxQ 2000 plate shaker (Thermo Fisher 
Scientific Inc, MI) at room temperature. Absorbances were 
measured at 570 nm using a Stat FaxR 4200 plate reader 
(Awareness Technology, Inc., FL). The cell viability was expressed as 
a percentage of control and the concentration that induces 50% of 
maximum inhibition of cell proliferation (IC50) were determined 
using Graph Pad Prism version 5 software (Graph Pad software Inc, 
CA) [16, 17]. 
Cell cycle analysis (DNA-Flow Cytometry Analysis) 
MCF-7 cells at a density of 4 x106 cell by T 75 flasks were exposed to 
(Compound X) at its IC50for 24 h. The cells then were collected by 
trypsinization, washed in PBS and fixed in absolute ice-cold alcohol. 
Thereafter, cells were stained using Cycle TESTTM PLUS DNA 
Reagent Kit (BD Biosciences, San Jose, CA) according to the 
manufacturer’s instructions. Cell-cycle distribution was determined 
using a FACS Caliber flow cytometer (BD Biosciences, San Jose, CA). 
Datasets  
All molecular modeling studies (3D-QSAR and pharmacophore 
model) were performed using the molecular modeling software 
package DS 2.5 software (Discovery Studio 2.5, Accelrys, Co. Ltd). 
A dataset of 16 of the synthesized compounds was used as a training set 
with heir inhibitory activities in IC50 (μM) was used in present study.  
Development of QSAR model 
A set of 13 of the synthesized compounds was used as a training set 
for the QSAR modeling. This test set displayed variable anticancer 
activities representing potent, moderate and weak anticancer 
activity. The most active compound 7a along with one of the 
moderate 5d and one of the week compounds 3b were used as 
statistical outliers. Molecular descriptors were calculated for each 
compound employing a “Calculate Molecular Properties” module 
which used for calculating different molecular properties for the 
training set compounds. 2D Descriptors involved: AlogP, molecular 
property counts, surface area and volume and topological 
descriptors while the 3D descriptors involved: Dipole, jurs 
descriptors, principle moments of inertia, shadow indices, and 
surface area and volume was employed. Genetic function 
approximation (GFA) was utilized to search for the best possible 
QSAR regression equation capable of correlating the variations in 
the biological activities of the training compounds with variations in 
the generated descriptors, i.e., multiple linear regression modeling 
(MLR). Different descriptors such as ES_Sum_dsN (Calculates the 
sums of the Electrotopological State (E-state) values of each atom 
type), Dipole_mag (3D electronic descriptors that indicates the 
strength and orientation behavior of a molecule in an electrostatic 
field), Jurs_WNSA_3 (the surface-weighted charged partial surface 
areas ''set of six descriptors'' (Jurs_WPSA_1, Jurs_WPSA_2, 
Jurs_WPSA_3, Jurs_WNSA_1, Jurs_WNSA_2 and Jurs_WNSA_3) 
obtained by multiplying descriptors 1 to 6 by the total molecular 
solvent-accessible surface area and dividing by 1000, Jurs 
descriptors are those ones that combine shape and electronic 
information to characterize molecules) were utilized in the models 
generated. Experimental anticancer activities, measured as IC50 in 
µM were used for the QSAR modeling. 
The QSAR model was validated employing leave-one-out cross-
validation by setting the folds to a number much larger than the 
number of samples, r2 (squared correlation coefficient value) and r2 
prediction (predictive squared correlation coefficient value) [18], 
residuals between the predicted and experimental activity of the test 
set and training set. Statistical outliers were identified from 
experimental versus predicted plots. 
Pharmacophore modeling 
The 3D-QSAR Pharmacophore Generation protocol (Catalyst 
HypoGen algorithm) was used to derive structure-activity 
relationship hypothesis models (3D-QSAR pharmacophore models). 
HypoGen identifies features common to the active compounds and 
excludes features common to the inactive ones within 
conformationally allowable regions of space. It further estimates the 
activity of the newly synthesized and tested compounds using 
regression parameters. Thus, a training set of the 16 synthesized 
compounds were used in this study to construct a pharmacophore 
model using hydrogen bond acceptor (HBA), hydrogen bond donor 
(HBD), hydrophobic (H), ring aromatic (RA) and positive ionizable 
(PosIon) chemical features.  
RESULTS AND DISCUSSION 
The route adopted for the preparation of target pyrazoles 3 and 
pyrazolo[1,5-a]pyrimidine derivatives 5, 7 and 9 are depicted in 
Schemes 1 and 2 respectively.  
 
 
Scheme 1: Synthesis of compounds 3a, b 
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The diazonium salt of 4-aminoacetophenone 1 was coupled with 
malononitrile in ethanol using sodium acetate, [12, 19-23] to afford 
2-[(4-acetylphenyl)diazenyl] malononitrile 2 [12]. Cycloaddition of 
compound 2 with hydrazine hydratein molar ratios 1:1 [20-24] or 
1:2, furnished 3,5-diaminopyrazolederivatives 3a and 3b 
respectively. The structures of 3a,b were well established from their 
microanalytical and spectral data. The IR spectrum of 3a revealed 
the appearance of two NH2 and NH at 𝞴𝞴max 3381 and 3268 cm-1 with 
the lack of CN band of the parent 2. Its 1HNMR spectrum (DMSO-d6) 
showed two singlet at δ 6.35 and 10.80 ppm corresponding to NH2 
and NH (exchangeable with D2O). Moreover, new pyrazolo [1,5-
a]pyrimidine derivatives 5a-f were obtained upon 
cyclocondensation of 3a, b with different chalcones 4a-c in 
EtOH/pip. [25], while compounds 7a-f were prepared via 
cycloaddition [19] of 3a, b with various arylidenemalononitriles 6a-c 
in the same reaction condition. Finally treatment of 3a, b with ethyl 
2-cyano-3-ethoxyacrylate 8a or 2-(ethoxymethylene) malononitrile 
8b in EtOH/TEA [19, 26] yielded the novel pyrazolo[1,5-
a]pyrimidine derivatives 9a, b respectively. Elemental and spectral 
analysis of 5a-f, 7a-f and 9a, b were in agreement with their 
structures. Compound 5b displayed the appearance of two singl et at 
δ 2.46 and 2.62 ppm corresponding to two methyl protons and 
showed characteristic singlet for pyrimidine-H at δ 7.78 ppm. In 
addition its 13C NMR spectrum showed 2 singlet at δ 21.57 and 27.22 
ppm corresponding to two methyl groups. The IR spectrum of 
7brevealed a new band for CN at 𝞴𝞴max 2210, while its 1HNMR 
spectrum (DMSO-d6) showed singlet at δ 3.87 ppm corresponding to 
three protons of the OCH3 group. 9a IR spectrum demonstrated a 
band at 1720 cm-1 related to carbonyl ester in addition to the band 
at 1670 cm-1 corresponding to acetyl C=O. Its 1HNMR spectra 
showed the characteristic triplet and quartet signals attributed to 
the ethyl protons in the region of 1.33-1.37 and 4.34-4.37 




Scheme 2: Synthesis of compounds 5, 7, 9 
 
Antitumor properties 
The in vitro antitumor activity against human breast cancer cells 
(MCF-7) of the 16 test compounds was achieved in the cell culture 
lab, College of Pharmacy, Al-Azhar University, Cairo, Egypt. 
Doxorubicin was used as a reference standard, and it showed IC50 = 
2.008 μM. 
The anticancer MCF-7 profile suggested that the test compounds 
showed variable activities compared to reference drug as shown in 
(table 1).  
It was observed that the 3, 5-diaminopyrazole 3a bearing a C=O 
group showed about 42 times the anticancer activity of its 
counterpart 3b (IC50 = 26.2, 1083.30 μM, respectively) which bears 
a C=NNH2 group instead. Additionally 3a was found to be 
approximately 1.27 times more potent than 4-[(3,5-diamino-1H-
pyrazol-4-yl)diazenyl]phenol (IC50 = 33 μM)[20]. Similarly, in 
pyrazolo[1,5-a]pyrimidine derivatives the most active compound 
was the 3-((4-acetylphenyl)diazenyl)-2,5-diamino-7-(4-chloro-
phenyl) pyrazolo[1,5-a]pyrimidine-6-carbonitrile 7a, with C=O 
group, IC50 = 3.25 μM; while its analog 7d showed poor anticancer 
activity (IC50 = 906.6 μM). The activity of the pyrazolo [1,5-
a]pyrimidine 7a displayed a 5 fold decrease upon replacement of the 
4-Cl-phenyl in position 7 with the 2,3-(OCH3)2Ph moiety as in 7c 
(IC50 = 15.4 μM). It is worth mentioning that the pyrazolopyrimidines 
7a, c bearing a C=O group were by far much more effective 
antiproliferative activity than their counterparts 7d, f containing 
C=NNH2 (IC50 = 3.25, 15.4, 906.6, 871.9 μM, respectively). 
Additionally, it was found that 7-Amino-N-(4-chlorophenyl)-6-cyano-
5-(4-fluorophenyl)-2-(4-methoxy-phenyl-amino) pyrazolo[1,5-a] 
pyrimidine-3-carboxamide prepared by Hassan et al.[27] is slightly 
potent than 7a, this may be due to the presence of a primary amine in 
7a while the other compound has lipophilic secondary amine. 
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On the contrary, pyrazolopyrimidines 5d, e, carrying C=NNH2, 
displayed more activity against human breast cancer MCF-7 cell line 
(IC50 = 40.2, 28.2 μM) than their analogs 5a, b (IC50 = 1083, 181 μM 
respectively).  
Moreover, poor activity was elicited by pyrazolopyrimidines 9a, b.  
Effect of 7a on cell cycle arrest in MCF-7 cells 
The most active compound 7a was selected for further study due to 
its effect on cell cycle progression in the MCF-7 cell line. The MCF-7 
cells were incubated with GI50 concentration of compound 7a for 24 
h and its effect on the normal cell cycle profile was analyzed. Flow 
cytometric analysis was performed to measure the effect of 
compound 7a on induction of cell cycle. As shown in fig. 2, the cells 
in S phase in the MCF-7 control group accounted for about 23.59%, 
while after cells treated with compound 7a, the ratio was 
approximately 32.66%. This shows that the cells were arrested in 
the S phase. Such increase was accompanied by a reduction of cells 
at the G2/M phase of the cell cycle, which resulted in an interference 
with the normal cell cycle distribution of this cell line. 
 
Table 1: IC50ʼs of the tested compounds against human breast cancer cells (MCF-7) 
 
 
Compound R1 R2 Ar` X IC50(mean±SD) 
3a - - - O 26.2±0.70 
3b - - - NNH2 1083.3±28.8 
5a Ph H 4-ClPh O 1083.3±28.8 
5b Ph H 4-CH3Ph O 181±1 



















7a NH2 CN 4-ClPh O 3.25±0.52 
7b NH2 CN 4-OCH3Ph O 948±7.2 
7c NH2 CN 2,3-(OCH3)2Ph O 15.4±0.51 
7d NH2 CN 4-ClPh NNH2 906.6±6.1 
7e NH2 CN 4-OCH3Ph NNH2 1243.3±40.4 

















Fig. 2: Bar chart shows the percentage of MCF7 cells at each phase 
of cell cycle in control cells and cells treated with compound 7a 
 
QSAR studies 
Equation one represents our best-performing QSAR model; Fig.3 
shows the corresponding scatter plots of the experimental versus 
estimated bioactivity values for the training set compounds, against 
MCF-7 cell line. Interestingly, the predicted anti-tumor activity by 
the QSAR model was very close to the experimentally observed, 
indicating that these models can be applied for prediction of more 
effective hits having the same skeletal framework as that of the 
potent antitumor compound. 
Equation 1 represents the best performing QSAR model for the 
activity against MCF-7 cell line. 




Fig. 3: Predicted versus experimental PIC50 values of the 
training set compounds against human breast cancer cell line 
(MCF-7) according to equation 1 (r2= 0.811) 
 
According to equation 1, the QSAR model was represented 
graphically by scattering plots of the experimental versus the 
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predicted bioactivity values–log IC50 for the training set compounds 
as shown in fig. 3. The method used to build the model was Least-
Squares, r2= 0.811, r2 (adj) = 0.748, r2 (pred) = 0.604, where r2 (adj) 
is r2 adjusted for the number of terms in the model; r2 (pred) is the 
prediction r2, equivalent to q2 from a leave-1-out cross-validation. 
Moreover, the MLR model developed in this work which involves 
three descriptors, reveals that the anticancer activity should 
correlate directly proportional with ES_Sum_dsN, Dipole_mag, Jurs_ 
WNSA_3. Additionally, the anticancer activities of the synthesized 
compounds are affected by these descriptors. 
QSAR validation 
Robustness of the established QSAR model was verified by using; 
Leave-one-out (LOO) internal validation r2= 0.811. Cross-validation 
was also employed where q2, which is equivalent to r2 (pred) was 
0.94. In addition, validation was employed by measuring the 
residuals between the experimental and the predicted activities of 
the training set c. f. supplementary material Furthermore, 
compounds 7a, 5d, 3b were used as statistical outliers where their 
pIC50 values were-0.511,-1.609,-3.041 respectively, their expected 
pIC50 values were-0.388,-1.963,-2.811 respectively with residuals-
0.123, 0.354,-0.230 respectively. The 2D QSAR studies, MLR model, 
showed high correlative and predictive abilities. Furthermore, the 
generated QSAR models performed to explore the structural features 
required for the observed antitumor property, revealed that the 
biological activities were influenced by the molecular descriptors: 
ES_Sum_dsN, Dipole_mag, Jurs_WNSA_3 of the synthesized 
compounds. 
Pharmacophore modeling 
It produced ten top-scored hypotheses based on the activity values 
of the training set molecules. The best ten hypotheses contained four 
features: HBD, HBA, H and RA. Hypo1 consisted of two HBA and one 
RA, as shown in Fig. 4 with constraint distances and angles between 
its features as described in (table 2), it also established the highest 
cost difference (118.89), lower errors (86.12), best correlation 
coefficient (0.86), maximum fit value (8.04) and lowest root mean 
square RMS of (2.45).  
This pharmacophore hypothesis generated was developed with a 
total cost value of (103.78), null cost value of (222.67), and fixed 
cost value of (52.98). The Fixed total cost was dependent on a 
summation of the cost components: weight cost, error cost and 
configuration cost.  
 
 
Fig. 4: Constraint distances and angles between features of the 
generated top pharmacophore model with the features 
considered hydrogen bond acceptors (HBA1 & HBA2) colored in 
green, and aromatic ring (RA) colored in orange
 
Table 2: Constraint distances and angles between features of the generated top pharmacophore model 
Constraint distances (Ao) Constraint angles (o) 
(HBA1-HBA2):7.694  HBA1, HBA2, RA: 27.59 
(RA-HBA1): 7.484 (RA-HBA2): 13.400  
 
Two key values were used for cost analysis: one is the difference 
between the fixed and null costs and another one is the difference 
between null and total cost (cost difference). The fixed cost 
represents a cost of the ideal theoretical hypothesis, which could 
absolutely predict the activity of compounds in the training set with 
the lowest deviation while null cost represented the cost of 
hypothesis with no features that estimate every activity to be the 
average activity. The difference between these two costs should be 
greater than or equal 70 bits to show 98% statistical significance of 
the model. The cost difference should be greater than 60 bits to 
represent a true correlation data. 
Higher cost difference and correlation value with low RMS and error 
values have been observed for Hypo1 when compared with the 
other hypotheses. Hence, Hypo1 was selected as the best hypothesis 
and employed for further analyzes, Fig. 4 shows, the Hypo1 chemical 
features with its geometric parameters. The most active compound 
7a in the training set a ligned in Hypo1 was shown in fig. 5. To verify, 
the prediction accuracy of Hypo1, Hypo1 was also able to estimate 
the activities of compounds in their own activity ranges. The 
experimental and estimated activities by Hypo1 for 16 training set 
compounds are shown in (table 3).  
The parameters were computed by regression analysis using the 
relationship of fit geometric value versus the activity. The better the 
geometric fit the greater the activity prediction of the compound. The fit 
function checks if the feature is mapped. It also contains a distance term, 
which measures the distance separating the feature on the molecule 
from the centroid of the feature in the pharmacophore hypothesis. Both 
terms are used to calculate the fit geometric value. 
The Fischer validation confidence level chosen is 98%, and the best-
generated pharmacophore significance was 82%. Further evaluation 
of the generated pharmacophore models was based on the 
correlation coefficient, which was found to be 0.86 that indicate the 
capability of the pharmacophore model to predict the activity of the 
training set compounds. 
In addition to cost analysis and Fischer validation, the 
pharmacophore model was validated through activity prediction of 
the synthesized structures as a training set. The predicted activities 
through the pharmacophore model are represented in (table 3) as 
well as their fit values. 
 
Fig. 5: The best-generated pharmacophore hypothesis with the 
features considered hydrogen bond acceptors (HBA1 and 
HBA2) colored in green, ring aromatic (RA) colored in orange 
and the synthesized structure 7a fitted in the pharmacophore 
with fit value 7.24 
 
Validation of pharmacophore modeling 
One of the significant methods in pharmacophore generation is 
validating the hypothesis. The generated hypotheses were mainly 
validated to check whether the best hypothesis selected the active 
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compounds during the screening process such as the percentage of 
active compounds picked from the dataset, correlation between the 
predicted and estimated values of the set test along with its 
efficiency in reducing true negatives and false positives. The selected 
Hypo1 was validated using the following methods; cost analysis, 
activity prediction, Fischer validation test. 
HypoGen selects the best hypotheses by applying a cost analysis. 
The overall cost of each hypothesis is calculated by summing three 
cost factors: a weight cost, an error cost, and a configuration cost. 
HypoGen also calculates two theoretical costs, the null and fixed costs 
that can be used to determine the significance of the selected 
hypothesis.  
The cost values of the optimized hypothesis should lie somewhere 
between these two costs. A larger difference between the fixed and 
null costs than that between the fixed and total costs signifies the 
quality of a pharmacophore model. 
 
Table 3: Fit values and estimated activities for the synthesized compounds mapped with the generated 3D-pharmacophore model 
Compound Predicted activity (IC50 μM) Experimental activity (IC50, mean) μM Fit value 
3a 361.22 26.2 5.33 
3b 1633.23 1083.3 4.67 
5a 396.08 1083.3 5.29 
5b 190.64 181 5.60 
5c 382.93 1250 5.30 
5d 55.19 40.2 6.14 
5e 32.79 28.2 6.37 
5f 484.64 97.5 5.20 





























IC50: Compound concentration required inhibiting the cell viability by 50%; each value is the mean of three values. 
 
The closer the cost value to the fixed cost and the further away it is 
from the null cost, the more statistically significant the hypothesis is 
believed to be. 
Fischer validation is another approach for pharmacophore model 
validation. This validation method checks the correlation between 
the chemical structures and biological activity. This method 
generates pharmacophore hypothesis using the same parameters as 
those used to develop the original pharmacophore hypothesis by 
randomizing the activity data of the training set compounds. The 
purpose of this study was not only to construct the pharmacophore 
model to predict the estimated activity of the compounds but also to 
employ the hypothesis on virtual screening to search novel scaffolds. 
In this work, we have built 3D pharmacophore models from 16 
newly synthesized compounds and the best quantitative 
pharmacophore model, Hypo1, consisted of three features like two 
HBA and one RA.  
For predicting activity, the correlation coefficient of Hypo1 was o.86, 
suggesting a good predictive power of the hypothesis for the 
majority of antitumor actives.  
From the overall analysis, we conclude that theHypo1 
pharmacophore could be used as the fast and accurate tool to assist 
discovery of novel anticancer agents. 
CONCLUSION 
In an effort to develop potent anticancer agents, pyrazoles 3a, b and 
pyrazolo[1,5-a]pyrimidines 5a-f, 7a-f, 9a, b were designed and 
synthesized. Anti-proliferative activity of the newly synthesized 
compounds was examined against MCF-7 breast cancer using MTT 
technique. Compound 7a was found to be the most active member 
against MCF-7 breast cancer (IC50= 3.25 μM), Further biological 
assessment of 7a using flow-cytometric analysis, revealed that it 
induced cell cycle arrest at S phase. 3D-QSAR pharmacophore 
modeling afforded a hypothesis with three chemical features: 2HBA, 
1RA. QSAR studies showed good predictive and statistically 
significant descriptor model with r2 0.811. The most important 
descriptors in the QSAR equation were ES_Sum_dsN, Dipole_mag, 
Jurs_WNSA_3. The combination of 3D-pharmacophore modeling and 
QSAR provides as an effective technique for understanding the 
observed pharmacological properties and thus could be adopted for 
developing effective lead structures. 
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